Disease activity and treatment-related toxicity are the most important contributors to poor prognosis in patients with ANCA-associated vasculitis (AAV). Sometimes, it is difficult to distinguish them. We present a case to highlight the challenges in the management of AAV and the complications with immunosuppression.